| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | HE6; EDDM6; GPR64; CBAVDX; TM7LN2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ADGRG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于ADGRG2抗体的代表性文献摘要(虚构示例，供参考格式)：
1. **"Development of a monoclonal antibody targeting ADGRG2 for prostate cancer detection"**
- Authors: Smith A, et al.
- 摘要：该研究开发了一种针对ADGRG2胞外域的单克隆抗体，验证其在前列腺癌组织中的特异性结合，并证明其可用于免疫组化检测ADGRG2过表达，提示其作为癌症生物标志物的潜力。
2. **"ADGRG2 antibody reveals its role in renal fibrosis via TGF-β signaling"**
- Authors: Chen L, et al.
- 摘要：通过ADGRG2特异性抗体阻断实验，发现ADGRG2通过调控TGF-β信号通路促进肾纤维化进程，为慢性肾病治疗提供新靶点。
3. **"ADGRG2 expression in glioblastoma and therapeutic antibody screening"**
- Authors: Wang Y, et al.
- 摘要：利用高通量抗体筛选技术获得靶向ADGRG2的人源化抗体，体外实验显示其可抑制胶质母细胞瘤细胞迁移和侵袭，提示其抗肿瘤应用前景。
注：以上文献为示例，实际引用需查询PubMed或Google Scholar获取真实研究。
ADGRG2 (Adhesion G Protein-Coupled Receptor G2), also known as GPR64. is a member of the adhesion GPCR family, characterized by a large extracellular N-terminal region containing adhesion-like domains and a seven-transmembrane helix structure typical of GPCRs. It plays roles in cellular signaling, tissue development, and cell-cell/matrix interactions, with expression observed in endothelial cells, immune cells, and specific epithelial tissues. ADGRG2 is implicated in physiological processes such as angiogenesis, immune regulation, and reproductive system function. Dysregulation of ADGRG2 has been linked to pathologies including prostate cancer, glioblastoma, and inflammatory disorders, highlighting its potential as a therapeutic target.
ADGRG2 antibodies are tools designed to detect, quantify, or inhibit this receptor in research and diagnostic contexts. These antibodies often target extracellular domains (e.g., the N-terminal fragment) or intracellular epitopes, enabling applications like Western blotting, immunohistochemistry, flow cytometry, and immunofluorescence. Monoclonal antibodies are preferred for specificity, while polyclonal antibodies may offer broader epitope recognition. Some ADGRG2 antibodies are engineered for functional studies, such as blocking ligand binding or modulating receptor activation. Validation typically includes testing in cell lines with confirmed ADGRG2 expression or knockout controls. As ADGRG2 gains attention in tumor microenvironment studies and biomarker discovery, reliable antibodies are critical for exploring its role in disease mechanisms and therapeutic development.
×
